Table 1 Summary Of Clinical Trials That Were Included In This Analysis
Author | N | Drug 1 | Drug 2 | Comparator | Follow-up | Mean Age (SD) | % Men | Mean FEV1 (SD) | % Current Smokers | Jadad Score | Prohibited COPD Drugs |
|---|---|---|---|---|---|---|---|---|---|---|---|
Casaburi 2002[39] | 921 | TI (18 ug OD) | None | PL | 49 weeks | 64 (9) | 76 | 1.02 (0.44) | NA | 3 | LABA/other anticholinergics |
Chan 2007[40] | 913 | TI (18 ug OD) | None | PL | 48 weeks | 66 (9) | 60 | 0.97 (0.38) | 32 | 3 | other anticholinergics, oral beta agonists |
Niewoehner 2005[41] | 1829 | TI (18 ug OD) | None | PL | 6 months | 68 (10) | 99 | 1.04 (0.4) | 30 | 3 | other anticholinergics; oral CS >20 mg/d |
Tashkin 2008[35] | 5993 | TI (18 ug OD) | None | PL | 9 months | 65 (8) | 75 | 1.10 (0.4) | 29 | 4 | other anticholinergics |
Tonnel 2008[42] | 554 | TI (18 ug OD) | None | PL | 6 months | 64 (10) | 86 | 1.36 (0.46) | 75 | 4 | other anticholinergics |
Vincken 2002[14] | 535 | TI (18 ug OD) | None | IP (40 ug QID) | 6 months | 64 (8) | 85 | 1.22 (0.43) | NA | 3 | LABAs, other anticholinergics |
Brusasco 2003[43] | 1207 | TI (18 ug OD) | SALM (50 ug BID) | PL | 6 months | 64 (9) | 76 | 1.10 (0.39) | NA | 3 | Insufficient details provided |
Vogelmeier 2008[44] | 640 | TI (18 ug OD) | FORM (10 ug BID) | PL | 24 weeks | 63 (9) | 78 | 1.52 (0.39) | NA | 3 | Insufficient details provided |
Tashkin 2008[20] | 1148 | BUD/FORM (320 ug/9 ug BID) | FORM (9 ug BID) | PL | 6 months | 63 (10) | 67 | 1.04 (0.41) | 41 | 4 | All prohibited except salbutamol |
Szafranski 2003[45] | 614 | BUD/FORM (320 ug/9 ug BID) | FORM (9 ug BID) | PL | 12 months | 64 (NA) | 80 | 0.98 (NA) | 35 | 3 | Only study drugs allowed |
Calverley 2003[46] | 765 | BUD/FORM (320 ug/9 ug BID) | FORM (9 ug BID) | PL | 12 months | 64 (NA) | 76 | 0.99 (0.33) | 34 | 3 | ICS, all bronchodilators except terbutaline, leukotriene modifiers, |
Rennard 2009[21] | 1470 | BUD/FORM (320 ug/9 ug BID) | FORM (9 ug BID) | PL | 12 months | 63 (9) | 64 | 1.01 (0.43) | 42 | 3 | All drugs except salbutamol |
Ferguson 2008[47] | 782 | SALM/FLU (50 ug/250 ug BID) | None | SALM (50 ug BID) | 12 months | 65 (9) | 56 | 0.94 (0.36) | 40 | 3 | ICS, LABA, TI |
Kardos 2007[48] | 998 | SALM/FLU (50 ug/500 ug BID) | None | SALM (50 ug BID) | 44 weeks | 63 (8) | 76 | 1.13 (0.41) | 42 | 3 | regular oral CS, LABA and TI |
Wedzicha 2008[15] | 1323 | SALM/FLU (50 ug/500 ug BID) | None | TI 18 ug OD | 24 months | 64 (NA) | 83 | 1.12 (NA) | 38 | 4 | All drugs except salbutamol |
Calverley 2003[49] | 1091 | SALM/FLU (50 ug/500 ug BID) | SALM (50 ug BID) | PL | 12 months | 64 (NA) | 73 | 1.26 (0.48) | 52 | 5 | Oral or inhaled CS or LABAs |
SCO30002 2008 [50] | 387 | SALM/FLU (25 ug/250 ug BID) | FP (250 ug BID) | PL | 12 months | 65 (9) | 82 | 1.54 (NA) | NA | 3 | Not specified |
SCO100540 2006[51] | 445 | SALM/FLU (50 ug/500 ug BID) | None | PL | 6 months | 66 (8) | 89 | 1.05 (0.37) | NA | 3 | Not specified |
Mahler 2002[52] | 506 | SALM/FLU (50 ug/500 ug BID) | SALM (50 ug BID) | PL | 24 weeks | 62 (NA) | 64 | 1.27 (NA) | 50 | 3 | Bronchodilators except salbutamol, oral CS |
Calverley 2007[13] | 4633 | SALM/FLU (50 ug/500 ug BID) | SALM (50 ug BID) | PL | 36 months | 65 (8) | 76 | 1.12 (0.4) | 43 | 4 | CS, LABA |
Zheng 2007[53] | 445 | SALM/FLU (50 ug/500 ug BID) | NA | PL | 24 weeks | 66 (8) | 89 | 1.05 (NA) | 22 | 4 | ICS, LABA |
Stockley 2006[54] | 634 | SALM (50 ug BID) | NA | PL | 12 months | 62 (9) | 77 | 1.30 (0.5) | 40 | 4 | TI or LABA |
SCO30002 2008[55] | 256 | SALM/FLU (50 ug/500 ug BID) | FLU (500 ug BID) | PL | 52 weeks | 64 (NA) | 82 | 1.50 (NA) | NA | 3 | Not specified |
SCO100470 2006 [56] | 1050 | SALM/FLU (50 ug/250 ug BID) | None | SALM (50 ug BID) | 6 months | 64 (9) | 78 | 1.67 (0.46) | NA | 3 | Not specified |
Anzueto 2009[57] | 797 | SALM/FLU (50 ug/250 ug BID) | None | SALM (50 ug BID) | 12 months | 65 (NA) | 54 | 1.17 (0.51) | 42 | 4 | All prohibited except salbutamol and ipratropium |
SCO40041 2008 [58] | 186 | SALM/FLU (50 ug/250 ug BID) | None | SALM (50 ug BID) | 3 years | 66 (9) | 61 | NA | NA | 3 | Not specified |
Wouters 2005 [59] | 373 | SALM/FLU (50 ug/500 ug BID) | None | SALM (50 ug BID) | 12 months | 64 (8) | 74 | 1.41 (0.48) | 37 | 4 | All prohibited except salbutamol, ipratropium and xanthines |